Kim_2025_Cancer.Res.Commun__

To develop a novel therapeutic strategy for lung cancer brain metastases by leveraging the tumor-tropic properties of genetically engineered Wharton's Jelly-derived mesenchymal stem cells (WJ-MSCs) as vehicles for dual-agent gene therapy across the blood-brain barrier. WJ-MSCs were transiently engineered using lipid nanoparticle (LNP) technology to co-express soluble TRAIL (sTRAIL) and the prodrug-activating enzyme carboxylesterase 1 (CES1). In vitro analyses assessed transfection efficiency, therapeutic protein expression, apoptosis induction, and maintenance of stemness. Tumor-homing capacity was evaluated via EGFP labeling and intracerebral tracking. Therapeutic efficacy was tested in subcutaneous and intracerebral lung cancer xenograft models using bioluminescent imaging, histopathology, and immunohistochemistry. In vivo treatment included intraperitoneal CPT-11 administration to assess synergy between CES1-mediated prodrug activation and sTRAIL-induced apoptosis. Modified WJ-MSCs exhibited preserved stem cell characteristics and strong tropism toward brain tumor sites. They secreted high levels of functional sTRAIL and CES1, enabling local activation of CPT-11 into SN-38 and inducing apoptosis through death receptor signaling (DR4/DR5). Combination therapy with WJ-MSCs-CES1.sTRAIL and CPT-11 significantly suppressed tumor growth in lung cancer brain metastasis models compared to control groups. The approach demonstrated selective cytotoxicity, minimal off-target effects, and favorable safety profiles. This study establishes a non-viral, transient gene delivery platform using autologous WJ-MSCs for dual-action gene therapy in lung cancer brain metastases. The combined use of CES1 and sTRAIL and enables precise tumor targeting and drug activation, offering a promising avenue for personalized, stem cell-based treatment strategies to improve outcomes in patients with brain metastatic lung cancer.